Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 185

The DOI matches its Crossref record.

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes

Open access
McSweeney, Peter A., Nash, Richard A., Sullivan, Keith M., Storek, Jan, Crofford, Leslie J., Dansey, Roger, Mayes, Maureen D., McDonagh, Kevin T., Nelson, J. Lee, Gooley, Theodore A., Holmberg, Leona A., Chen, C. S., Wener, Mark H., Ryan, Katherine, Sunderhaus, Julie, Russell, Ken, Rambharose, John, Storb, Rainer, Furst, Daniel E. · 2002 · Blood

Abstract

Systemic sclerosis (SSc) is a multisystem disease of presumed autoimmune pathogenesis for which no proven effective treatment exists. High-dose immunosuppressive therapy (HDIT) has been proposed as an investigational treatment for severe autoimmune diseases. Nineteen patients with poor-prognosis SSc underwent HDIT. The median age was 40 years (range, 23-61 years), the median modified Rodnan skin score (a measure of dermal sclerosis) was 31, and the median DLCO was 57%. Conditioning therapy involved 800 cGy total body irradiation (TBI) (± lung shielding to approximately 200 cGy), 120 mg/kg cyclophosphamide, and 90 mg/kg equine antithymocyte globulin. CD34-selected granulocyte–colony-stimulating factor–mobilized autologous blood stem cells provided hematopoietic rescue. With median follow-up at 14.7 months, the Kaplan-Meier estimated 2-year survival rate was 79%. Three patients died of treatment complications and one of disease progression. Two of the first 8 patients had fatal regimen-related pulmonary injury, a complication not found among 11 subsequent patients who received lung shielding for TBI. Overall, internal organ functions were stable to slightly worse after HDIT, and 4 patients had progressive or nonresponsive disease. As measured by modified Rodnan skin scores and modified health assessment questionnaire disability index (mHAQ-DI) scores, significant disease responses occurred in 12 of 12 patients evaluated at 1 year after HDIT. In conclusion, though important treatment-related toxicities occurred after HDIT for SSc, modifications of initial approaches appear to reduce treatment risks. Responses in skin and mHAQ-DI scores exceed those reported with other therapies, suggesting that HDIT is a promising new therapy for SSc that should be evaluated in prospective randomized studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.v100.5.1602.h81702001602_1602_1610

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 185

Metadata

Authors
McSweeney, P. A., Nash, R. A., Sullivan, K. M., Storek, J., Crofford, L. J., Dansey, R., Mayes, M. D., McDonagh, K. T., Nelson, J. L., Gooley, T. A., Holmberg, L. A., Chen, C. S., Wener, M. H., Ryan, K., Sunderhaus, J., Russell, K., Rambharose, J., Storb, R., & Furst, D. E.
Venue
Blood
Published
2002-09-01
Volume
100
Issue
5
Pages
1602-1610
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W1876338319
Cited by
185
References
0
FWCI
9.93
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. https://app.cochat.ai/papers/10.1182/blood.v100.5.1602.h81702001602_1602_1610
The paper
McSweeney, P. A., Nash, R. A., Sullivan, K. M., Storek, J., Crofford, L. J., Dansey, R., Mayes, M. D., McDonagh, K. T., Nelson, J. L., Gooley, T. A., Holmberg, L. A., Chen, C. S., Wener, M. H., Ryan, K., Sunderhaus, J., Russell, K., Rambharose, J., Storb, R., & Furst, D. E. (2002). High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood. https://doi.org/10.1182/blood.v100.5.1602.h81702001602_1602_1610

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.